Results 91 to 100 of about 54,075 (219)
Journal of Gastroenterology and Hepatology, EarlyView.ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad +10 more
wiley +1 more source
Experimental Physiology, EarlyView.Abstract Reduced cardiorespiratory fitness is common among breast cancer survivors and, although traditionally attributed to cardiac dysfunction, might also be related to peripheral skeletal muscle abnormalities. We examined peak and submaximal plantar‐flexion exercise and recovery kinetics for lower‐leg oxygen uptake (V̇O2${\dot V_{{{\mathrm{O}}_2}}}$)
Nathan R. Weeldreyer +11 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 1, Page 159-172, 1 July 2026.What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin +20 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang +5 more
wiley +1 more source
Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 333-350, June 2026.Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown +7 more
wiley +1 more source
Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 381-391, June 2026.ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern +8 more
wiley +1 more source
Cancer, Volume 132, Issue 10, 15 May 2026.ABSTRACT Over the past decade, clonal hematopoiesis (CH) has gained substantial attention as a prevalent, age‐associated phenomenon with major implications for hematologic malignancy, cardiovascular disease, and mortality. CH arises from the clonal expansion of hematopoietic stem cells and progenitor cells harboring somatic mutations, most commonly in ...
Christian H. Nenninger +7 more
wiley +1 more source
Molecular Oncology, Volume 20, Issue 5, Page 1220-1236, May 2026.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
FEBS Open Bio, Volume 16, Issue 5, Page 1030-1043, May 2026.Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu +5 more
wiley +1 more source
Coacervate‐Mediated Lysosome‐Targeting Antibody Delivery for Protein Degradation
Advanced Science, Volume 13, Issue 25, 4 May 2026.Targeting coacervates to the lysosome in the cytoplasm is a challenge. Here, we convert a tetrapeptide into lysosome‐targeting, membrane‐translocating coacervates. The lysosome‐sorting peptide coacervates facilitate coacervate‐mediated delivery of antibody antigen complexes and a PROTAC compound to the lysosome for the targeted degradation of cancer ...
Dingdong Yuan +7 more
wiley +1 more source